Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sona Nanotech Inc ( (TSE:SONA) ) has shared an announcement.
Sona Nanotech Inc. has announced the publication of its preclinical efficacy studies on Targeted Hyperthermia Therapy (THT) in the peer-reviewed journal ‘Frontiers in Immunology’. The studies demonstrate that Sona’s THT technology can convert immune-unresponsive ‘cold’ tumors into ‘hot’ immunogenic ones, effectively triggering a strong immune response. This breakthrough offers proof-of-concept for the company, supporting its plans to commence clinical trials in 2025 and enhancing its credibility with potential industry partners. The publication reinforces Sona’s commitment to gathering data to support future regulatory filings and expand its research into other cancer types.
More about Sona Nanotech Inc
Sona Nanotech Inc. operates in the biotechnology sector, focusing on the development of innovative cancer treatments. The company specializes in using proprietary biocompatible gold nanorods to deliver targeted hyperthermia therapy, aimed at reducing systemic toxicity in cancer treatments.
YTD Price Performance: -1.89%
Average Trading Volume: 20,159
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$27.41M
See more data about SONA stock on TipRanks’ Stock Analysis page.